CAR macrophages tuning the immune symphony of anti-cancer therapies

Chimeric antigen receptor (CAR) macrophages have broadened the landscape of anti-cancer immunotherapies to combat solid malignancies. Shah et al. introduce CARs to facilitate a CAR macrophage therapy, which aims to recruit and activate T/natural killer cells, further strengthening the overall immune response to decrease pancreatic cancer burden and metastatic spreading. Chimeric antigen receptor (CAR) macrophages have broadened the landscape of anti-cancer immunotherapies to combat solid malignancies. Shah et al. introduce CARs to facilitate a CAR macrophage therapy, which aims to recruit and activate T/natural killer cells, further strengthening the overall immune response to decrease pancreatic cancer burden and metastatic spreading. Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancerShah et al.Cell Stem CellApril 24, 2024In BriefYu and colleagues demonstrated that CAR macrophages derived from human induced pluripotent stem cells offer potential as an alternative to CAR-T cells for treating solid tumors. The allogeneic CAR macrophages targeting PSCA on tumor cells are safe with strong antitumor efficacy in pancreatic cancer mouse models, suggesting a promising path for clinical application. Full-Text PDF